Abstract:Motivation: Identifying and developing novel therapeutic effects for existing drugs contributes to reduction of drug development costs. Most of the previous methods focus on integration of the heterogeneous data of drugs and diseases from multiple sources for predicting the candidate drug-disease associations. However, they fail to take the prior knowledge of drugs and diseases and their sparse characteristic into account. It is essential to develop a method that exploits the more useful information to predict the reliable candidate associations. Results: We present a method based on non-negative matrix factorization, DisDrugPred, to predict the drug-related candidate disease indications. A new type of drug similarity is firstly calculated based on their associated diseases. DisDrugPred completely integrates two types of disease similarities, the associations between drugs and diseases, and the various similarities between drugs from different levels including the chemical structures of drugs, the target proteins of drugs, the diseases associated with drugs and the side effects of drugs. The prior knowledge of drugs and diseases and the sparse characteristic of drug-disease associations provide a deep biological perspective for capturing the relationships between drugs and diseases. Simultaneously, the possibility that a drug is associated with a disease is also dependant on their projections in the low-dimension feature space. Therefore, DisDrugPred deeply integrates the diverse prior knowledge, the sparse characteristic of associations and the projections of drugs and diseases. DisDrugPred achieves superior prediction performance than several state-of-the-art methods for drug-disease association prediction. During the validation process, DisDrugPred also can retrieve more actual drug-disease associations in the top part of prediction result which often attracts more attention from the biologists. Moreover, case studies on five drugs further confirm DisDrugPred's ability to discover potential candidate disease indications for drugs.

A Pathway Profile-Based Method for Drug Repositioning

Drug repositioning by applying 'expression profiles' generated by integrating chemical structure similarity and gene semantic similarity.

A Computational Strategy for Drug Repositioning Based on Support-Vector Regression Algorithm

Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines

Predicting Targeted Polypharmacology for Drug Repositioning and Multi- Target Drug Discovery

Biomedical Data and Computational Models for Drug Repositioning: a Comprehensive Review

Drug Repositioning By Kernel-Based Integration Of Molecular Structure, Molecular Activity, And Phenotype Data

Computational drug repositioning: from data to therapeutics.

Computational Drug Repositioning Using Collaborative Filtering Via Multi-Source Fusion

A Review of Current In Silico Methods for Repositioning Drugs and Chemical Compounds

A Study on Methodologies of Drug Repositioning Using Biomedical Big Data: A Focus on Diabetes Mellitus

Computational Drug Repositioning Using Meta-Path-based Semantic Network Analysis.

A Review of Recent Developments and Progress in Computational Drug Repositioning.

Review of Drug Repositioning Approaches and Resources

Repositioning Drugs For Breast Cancer Based On The Identification Of Cancer Related Signaling Pathways

Drug Repositioning by Prediction of Drug's Anatomical Therapeutic Chemical Code Via Network-Based Inference Approaches.

DrugRepPT: a Deep Pre-Training and Fine-Tuning Framework for Drug Repositioning Based on Drug's Expression Perturbation and Treatment Effectiveness.

Construction of Drug Network Based on Side Effects and Its Application for Drug Repositioning

Drug Repositioning Through Integration of Prior Knowledge and Projections of Drugs and Diseases

Review of Drug Repositioning of Computational Approach

In silico drug repositioning based on drug-miRNA associations